Niraj Sharma: Andexxa – Now Voluntarily Withdrawn From the U.S. Market
Niraj Sharma, Cardiac Electrophysiologist/Cardiologist at Northside Hospital, shared on LinkedIn:
“EP Edge | BREAKING NEWS
Just when we thought reversal was the solution…
Andexxa (andexanet alfa) — the first-in-class reversal agent for factor Xa inhibitors (apixaban, rivaroxaban) — has now been voluntarily withdrawn from the U.S. market, with U.S. sales ending December 22, 2025
WHAT CHANGED?
The decision follows FDA review of post-marketing safety data and results from the ANNEXA-I confirmatory randomized trial, required after Andexxa’s 2018 accelerated approval.
Bottom line from the FDA:
The risks now outweigh the benefits.
KEY SAFETY SIGNALS (ANNEXA-I)
Compared with usual care, patients receiving Andexxa had:
Higher thrombotic events:
14.6% vs 6.9%
Higher thrombotic-related deaths at 30 days:
2.5% vs 0.9%
Earlier thrombotic events:
53% of Andexxa-treated patients had earlier events vs 6.3% with usual care
Importantly, Andexxa already carried a boxed warning, but these findings confirmed a clinically meaningful safety signal, not just a theoretical risk
A REGULATORY LESSON
Accelerated approval was based on anti-FXa activity reduction (a surrogate endpoint)
The required outcomes trial failed to confirm net clinical benefit
This is exactly why post-approval trials matter
WHY THIS MATTERS TO PRACTICE
This is not just about one drug.
- Loss of the only specific Xa reversal agent in the U.S.
- Forces re-evaluation of DOAC bleeding protocols
- Reinforces caution with surrogate endpoints
- Highlights the need for safer reversal strategies
EP EDGE TAKEAWAY
Innovation is essential —
but safety must survive real-world evidence.
As clinicians, we owe our patients both speed and certainty.”
Get insights from Hemostasis Today.
-
Apr 3, 2026, 05:59Nathan Connell: How the 2021 VWD Guidelines Are Actually Changing Real – World Practice
-
Apr 3, 2026, 05:28Tareq Abadl: How Iron Profile Reveals Hidden Insights about Blood Health and Iron Balance
-
Apr 3, 2026, 04:49Niraj Sharma: Breaking News Special Edition, CHAMPION-AF, CLOSURE-AF, PRAGUE-17, and Why LAAC Still Does Not Dethrone Contemporary Anticoagulation
-
Apr 2, 2026, 18:32Niyas Khalid: A Rare Case of Venous Ischemic Pancreatitis Redefining Diagnosis
-
Apr 2, 2026, 18:16Saravanan Subramaniam: How Extracellular Histones Act as Key Drivers of Thromboinflammation
-
Apr 2, 2026, 18:06Rob Molhoek Brings Invaluable Insights on Stroke Awareness and Care Improvements – Stroke Foundation
-
Apr 2, 2026, 17:21Paul Bolaji: Phase 2 of the Nigeria National Stroke Registry Is Now Live
-
Apr 2, 2026, 17:13Catherine Jennings: Marking Today as an Important Step Forward for Patients With PE
-
Apr 2, 2026, 17:11Arun V. J: Our Clinical Audit on Transfusion Safety Selected for Presentation at CAHOCON 2026